Cerezyme Articles
GSK inks $300m rare diseases alliance with Angiochem
28 February 2012
Ongoing supply problems for Genzyme’s Cerezyme
19 September 2011
Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv
1 September 2011
Genzyme’s 2nd-qtr 2010 profits plunge on continuing Cerezyme and Fabrazyme supply problems
22 July 2010
US FDA to take enforcement action regarding Genzyme’s Allston plant, including financial penalties
25 March 2010
Icahn seeks to influence Genzyme, nominating four board directors
23 February 2010
Genzyme’s 4th quarter 2009 earnings plunge due to manufacturing problems for two leading products; expands research in Europe
18 February 2010
Shire presents strong Ph III velaglucerase alfa data in Type 1 Gaucher disease and Genzyme Ph II with eliglustat at LDN meeting
12 February 2010
Pfizer to pay Protalix up to $115 million in Gaucher's disease treatment deal; Genzyme’s Cerezyme supply
2 December 2009
Shire’s Gaucher disease drug enters fast-track EU approval process
27 November 2009
More bad news for Genzyme as US FDA delays Lumizyme application
17 November 2009
FDA finds trash particles in Genzyme’s drugs, leading firm to advise health care providers
16 November 2009
Third-quarter 2009 profit sinks at Genzyme, on production woes
22 October 2009
Genzyme updates on Cerezyme and Fabrazyme sales now supply back on line
24 September 2009
Genzyme's 2008 profit down on costs
23 February 2009
Genzyme's 3rd-qtr 2008 profit down 25%
3 November 2008
Genzyme's 2nd qtr profit hit by license cost
4 August 2008
Genzyme's 1st-qtr revenues jump 25%
5 May 2008
Reduced dosage temptation for expensive Gaucher's drug
24 March 2008
Strong third quarter for Genzyme: GAAP net income reaches $159M on the back of good sales
5 November 2007
Genzyme's 2nd-qtr net income jumps 4%
6 August 2007
Genzyme's 1st-qtr net income soars 57%
7 May 2007
Genzyme's 2nd-qtr 2006 revenue rises 19%
24 July 2006
Genzyme guidance upped on good 2nd qtr
25 July 2005
Genzyme's 1st-qtr revenues up 28%
25 April 2005
Genzyme $57.3M net loss for 4th qtr 2004
28 February 2005
Myzozyme MAA lifts Genzyme
10 January 2005
Genzyme posts 1st-qtr net income of $67.9M
26 April 2004
UK judicial decison impacts Genzyme
22 March 2004
Genzyme swings to loss on acquisition costs
27 October 2003
EC OKs new use for Genzyme's Cerezyme
22 September 2003
Genzyme receives rare boost in 2nd qtr
21 July 2003
Cerezyme closer to expanded use in EU
23 June 2003
US orphan drug costs "up 40% per year"
9 June 2003
FDA clears Genzyme, BioMarin drug for MPS
12 May 2003
Genzyme revenues up 12% in 2nd-qtr
22 July 2002
Genzyme General revises 2002 financial guidance
24 June 2002
Unspectacular quarter at Genzyme General
29 April 2002
Major increase in net losses at OGS
1 April 2002
Major increase in net losses at OGS
1 April 2002
Renagel sales leap at Genzyme General
18 March 2002
Oxford GlycoSciences pinning hopes on Vevesca approval
25 September 2001
OGS completes NDA submission to FDA for Vevesca
22 August 2001
OGS' Vevesca is under review by EMEA
12 July 2001
Genzyme expanding in Ireland and USA
31 May 2001
Genzyme 4th qtr net income rises 38%
9 March 2001
Genzyme hit by delay to Fabrazyme; opportunity for TKT?
2 January 2001
OGS pleased with new Gaucher disease study
4 May 2000
US biotech drug sales to grow 13% pa to 2002
29 March 1999
Genzyme General to focus on therapeutics
8 March 1999
MPS-I Treatment Set For Filing In 1999?
4 November 1998
Healthy Second-Quarter Growth For US Drug Firms
29 July 1998
Strong Revenue Growth At Genzyme General
11 March 1998
CPMP Meeting Views Tallow Derivatives
30 December 1998
CPMP July Plenary Meeting
5 August 1997
Record 1996 Revenues For Genzyme General Division
13 January 1997
US Drug Lag Does Not Exist, Claims FDA Study
15 January 1996
US Drug Firms Perform Well In Third Quarter
6 November 1995
Targeted Genetics Starts Gaucher's Disease Gene Therapy Trial
30 October 1995
Genzyme Buys Rest Of IG Labs' Shares
16 October 1995
Lowest Possible Ceredase/Cerezyme Dose Sought
13 March 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Lower Earnings For Some US Drugmakers In 3rd Qtr
7 November 1994
CEREZYME APPROVED IN USA
6 June 1994
Showing 1-90 of 90 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
